8-K: Evolus Reports Q1 2026 Results: Positive Adjusted EBITDA

Evolus, Inc. announced its first quarter 2026 financial results, achieving its second consecutive quarter of positive Adjusted EBITDA and reaffirming its full-year outlook.

Summary

• Evolus, Inc. reported first quarter 2026 net revenues of $73.1 million, a 7% increase year-over-year.
• The company achieved a positive Adjusted EBITDA of $0.6 million, marking the second consecutive quarter of profitability.
• This compares to an Adjusted EBITDA loss of $5.5 million in the first quarter of 2025.
• GAAP operating loss for the quarter was $6.8 million.
• Full-year 2026 net revenue guidance remains between $327 million and $337 million, representing 10% to 13% growth.
• Non-GAAP operating expenses for 2026 are projected between $210 million and $216 million.
• The company expects to achieve a low- to mid-single digit Adjusted EBITDA margin for the full year 2026.
• Evolus Rewards program has nearly 1.5 million members, with redemptions reaching an all-time high.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with the company demonstrating continued progress towards profitability and reaffirming its financial outlook, despite a GAAP operating loss.

Positives

• Achieved second consecutive quarter of positive Adjusted EBITDA ($0.6 million).
• Total net revenues increased by 7% to $73.1 million in Q1 2026 compared to Q1 2025.
• Significant improvement in Adjusted EBITDA from a loss of $5.5 million in Q1 2025 to a gain of $0.6 million in Q1 2026.
• Reaffirmed full-year 2026 net revenue guidance of $327 million to $337 million (10-13% growth).
• Evolus Rewards program continues to grow, approaching 1.5 million members, with a 27% increase year-over-year.
• Customer reorder rates remain strong at approximately 71%.
• Gross profit margin was 66.9% and adjusted gross profit margin was 68.0%.

Negatives

• Reported a GAAP operating loss of $6.8 million for the first quarter of 2026.
• Cash and cash equivalents decreased from $53.8 million at the end of 2025 to $49.8 million at the end of Q1 2026.
• Net loss for the quarter was $10.7 million, or $0.16 per share.

Risks

• Potential impact of a 15% tariff on patented pharmaceuticals from South Korea, which would apply to Jeuveau starting September 29, 2026, though the company believes it has flexibility to mitigate near to medium-term impacts.
• Evolysse is currently subject to a 10% tariff.
• Uncertainties associated with complying with Medytox Settlement Agreements.
• Reliance on consumer discretionary spending and unfavorable global economic conditions, including trade disputes and tariffs.
• Competition and market dynamics in the aesthetic injectable market.
• Ability to successfully launch and commercialize products in new markets.
• Maintaining regulatory approvals for Jeuveau and Evolysse, and obtaining approvals for new product candidates.
• Reliance on Symatese for Evolysse HA gel product approvals in the U.S.

Future Outlook

The company reaffirms its full-year 2026 guidance for total net revenues between $327 million and $337 million (10-13% growth) and non-GAAP operating expenses between $210 million and $216 million. Evolus expects to achieve a low- to mid-single digit Adjusted EBITDA margin in 2026. Long-term, the company projects total net revenue between $450 million and $500 million by 2028, with Adjusted EBITDA margins of 13% to 15%.

Management Comments

• "We started 2026 with a second consecutive quarter of positive Adjusted EBITDA, delivering profitability in what is seasonally our lowest revenue quarter."
• "This performance reflects continued strength of the business and the benefit from structural improvements we implemented in 2025."
• "Importantly, achieving profitability in the first quarter further reinforces the durability of our operating model and our confidence in achieving full-year profitability in 2026."
• "Underlying demand across the business remains healthy and consistent with the momentum we exited 2025."
• "Our performance continues to be supported by strong engagement from our existing customer base, expansion across national accounts, and ongoing growth in our international markets."
• "Our commercial platform continues to scale effectively, supported by strong growth in Evolus Rewards, which now approaches 1.5 million members, along with increasing customer penetration and consistent repeat utilization."
• "With a more efficient cost structure and expanding operating leverage, we reiterate our full-year guidance to deliver positive Adjusted EBITDA and double-digit revenue growth in 2026, while continuing to invest in long-term value creation."

Industry Context

StockSavvy.ai notes that Evolus's focus on building an aesthetic portfolio and its performance in the competitive aesthetic injectable market, particularly with Jeuveau and the expanding Evolysse line, aligns with broader industry trends towards personalized beauty solutions and the growth of minimally invasive aesthetic procedures. The company's digital platform and loyalty program are key differentiators in customer engagement.

Comparison to Industry Standards

• Evolus's Adjusted EBITDA margin of 0.8% in Q1 2026 is a positive step towards its full-year target of low- to mid-single digits, which is a key metric for assessing operational efficiency in the aesthetics industry.
• The company's revenue growth of 7% in Q1 2026, while solid, is within the range of many specialty pharmaceutical and beauty companies, but the focus on double-digit growth for the full year ($327M-$337M) aims to outpace broader market growth.
• Competitors like Allergan (now AbbVie) with its Botox and Juvederm lines, and Galderma with Restylane, operate in a similar space, with varying degrees of profitability and market share. Evolus's strategy to differentiate through its digital platform and loyalty program (Evolus Rewards) is a notable approach to customer retention compared to more traditional sales models.
• The company's stated long-term outlook of 13-15% Adjusted EBITDA margins by 2028 suggests an ambition to reach profitability levels comparable to established players in the aesthetics market, provided sustained growth and operational leverage are achieved.

Stakeholder Impact

• Shareholders: Positive impact from achieving profitability and reaffirming growth outlook, potentially supporting share price. Negative impact from GAAP operating loss and decrease in cash reserves.
• Employees: Continued focus on growth and efficiency may lead to job security and potential for future expansion.
• Customers: Continued availability of Jeuveau and Evolysse products, with potential for new product launches.
• Suppliers: Continued business operations and potential for increased demand with revenue growth.

Next Steps

• Launch of all four injectable hyaluronic acid gels under the Estyme brand in Europe in mid-May 2026.
• Anticipate U.S. approval of Evolysse Sculpt later in 2026.
• Continue to invest in long-term value creation.
• Execute on strategy to build a global performance beauty company.
• Continue to scale commercial platform and grow Evolus Rewards program.

Key Dates

Recommendation

The company is showing positive operational momentum with consecutive quarters of positive Adjusted EBITDA and reaffirmed guidance. However, the GAAP operating loss, decrease in cash, and ongoing risks related to tariffs and competition warrant a cautious 'hold' stance until sustained profitability and stronger cash flow generation are demonstrated.

Keywords

Evolus, Jeuveau, Evolysse, Aesthetic, Financial Results, Adjusted EBITDA, Revenue, Form 8-K